What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?

BJU International

Volumn 103, Issue 12, 2009, Pages 1641-1646

  Oudard, Stéphane ^a,b,d   Banu, Eugeniu ^a   Medioni, Jacques ^a   Scotte, Florian ^a   Banu, Adela ^a   Levy, Eric ^a   Wasserman, Johana ^a   Kacso, Gabriel ^c   Andrieu, Jean Marie ^a  

^a Departments of Gynecologic Oncology   (France)

^b ECOLE NATIONALE VÉTÉRINAIRE D ALFORT   (France)

^c Cancer Institute Ion Chiricuta Cluj Napoca   (Romania)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Bone pain; Hormone refractory; Prognostic factor; Prostate cancer; Survival

Indexed keywords

DOCETAXEL; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE PAIN; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROSTATE CANCER; REFRACTORY PERIOD; RISK ASSESSMENT;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; MITOXANTRONE; PAIN; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 67149133196     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.08283.x     Document Type: Article

References (31)

1. Body JJ, Facon T, Coleman RE et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006 12 : 1221 8
2. Shulman MJ, Karam JA, Benaim EA. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer. Urology 2004 63 : 732 6
3. Kantoff PW, Halabi S, Conaway M et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999 17 : 2506 13
4. Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian Randomized Trial with Palliative End Points. J Clin Oncol 1996 14 : 1756 64
5. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004 351 : 1513 20
6. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004 351 : 1502 12
7. Ryan CJ, Eisenberger M. Chemotherapy for hormone-refractory prostate cancer: now it's a question of 'when?'. J Clin Oncol 2005 23 : 8242 6
8. Berthold DR, Sternberg CN, Tannock IF. Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol 2005 23 : 8247 52
9. Sowery RD, So AI, Gleave ME. Therapeutic options in advanced prostate cancer: present and future. Curr Urol Rep 2007 8 : 53 9
10. Pienta KJ, Smith DC. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin 2005 55 : 300 18
11. Bral EE. Caring for adults with chronic cancer pain. Am J Nurs 1998 98 : 26 32
12. Oudard S, Banu E, Scotte F et al. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann Oncol 2007 18 : 1828 33
13. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med 2002 21 : 2917 30
14. Pachynski RK, King C, Srinivas S. Prostate specific antigen doubling time (PSADT) in patients with hormone refractory prostate cancer (HRPC) undergoing docetaxel chemotherapy as a predictor of overall survival. J Clin Oncol 2007 25 : (Abstract) 15556
15. Semeniuk RC, Venner PM, North S. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer. Urology 2006 68 : 565 9
16. Oudard S, Banu E, Banu A et al. Docetaxel versus mitoxantrone as first-line chemotherapy for hormone-refractory prostate cancer patients. A meta-analysis of 3-years overall survival results. Proc Am Soc Clin Oncol 2005 411 : (Abstract) 4634
17. Oudard S, Banu E, Beuzeboc P et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 2005 23 : 3343 51
18. Mike S, Harrison C, Coles B, Staffurth J, Wilt TJ, Mason MD. Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev 2006 : CD005247
19. Collins R, Fenwick E, Trowman R et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Health Technol Assess 2007 11 : iii iv, xv xviii, 1 179
20. Mancuso A, Oudard S, Sternberg CN. Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments. Crit Rev Oncol Hematol 2007 61 : 176 85
21. Oh WK, George DJ, Kaufman DS et al. Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report. Semin Oncol 2001 28 : 40 4
22. Bamias A, Bozas G, Antoniou N et al. Prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience. Eur Urol 2008 53 : 323 31
23. Armstrong AJ, Garrett-Mayer E, Ou Yang YC et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007 25 : 3965 70
24. Nelius T, Klatte T, Yap R et al. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer. BJU Int 2006 98 : 580 5
25. Halabi S, Vogelzang NJ, Kornblith AB et al. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 2008 26 : 2544 9
26. Ernst DS, Tannock IF, Winquist EW et al. Randomized, double-blind, controlled trial of mitoxantrone-prednisone and clodronate versus mitoxantrone-prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 2003 21 : 3335 42
27. Fizazi K, Gravis G, Culine S. The GETUG 12 trial, a phase III randomized trial of docetaxel-estramustine in high risk localized prostate cancer: clinical design and current status. Prostate cancer symposium. Proc Am Soc Clin Oncol 2006 153 : 231s, Abstract
28. Gravis G, Fizazi K, Joly F et al. Randomized phase III study comparing docetaxel and androgen deprivation therapy (ADT) versus ADT alone in androgen dependent metastatic prostate cancer (GETUG-15-0403): A French national multicentric study sponsored by the French Federation des Centres. Proc Am Soc Clin Oncol, prostate cancer symposium 2007 154 : Abstract 161
29. Oudard S, Banu E, Latorzeff I et al. Non-metastatic high-risk prostate cancer patients with biochemical relapse only after local treatment. A prospective randomized phase III study comparing hormonal therapy +--docetaxel. Prostate Cancer Symposium. Proc Am Soc Clin Oncol 2008 155 : Abstract 212
30. George DJ, Halabi S, Shepard TF et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001 7 : 1932 6
31. Halabi S, Small EJ, Hayes DF, Vogelzang NJ, Kantoff PW. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583. J Clin Oncol 2003 21 : 490 5